 |
answer text |
<p>On 10 August 2022, the Department referred tixagevimab and cilgavimab (Evusheld)
to the National Institute for Health and Care Excellence (NICE) to evaluate its clinical
and cost effectiveness for preventing COVID-19. Between 29 July and 12 August, NICE
consulted with stakeholders on the suggested remit, draft scope and list of consultees
and commentators.</p><p>NICE has commenced this evaluation and currently expects to
publish draft guidance in April 2023, with final guidance to follow in May 2023. In
discussion with AstraZeneca, NICE is expediting the appraisal process by bringing
forward the deadline for the manufacturer’s evidence submission.</p>
|
 |
